$ACHL News
Last published 1y ago
- 1y agoACHLAchilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC DeregistrationGlobeNewswireLONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist
- 1y agoACHLAZNAchilles Therapeutics Announces Sale of Technology Assets to AstraZenecaGlobeNewswire- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024
- 1y agoACHLAchilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketGlobeNewswireLONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq")
- 1y agoACHLAchilles Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 – LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc
- 2y agoACHLAchilles Therapeutics Announces Strategic UpdateGlobeNewswire–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024
- 2y agoACHLAchilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business UpdatesGlobeNewswire– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use
- 2y agoACHLARCTAchilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer VaccinesGlobeNewswireCombines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses
- 2y agoACHLAchilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireLONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
- 2y agoACHLAchilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash
- 2y agoACHLAchilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsGlobeNewswire– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate
- 2y agoACHLAchilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningGlobeNewswire– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients
- 2y agoACHLAchilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceGlobeNewswireLONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
- 2y agoACHLAchilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity PredictionGlobeNewswireLONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
- 2y agoACHLAchilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsGlobeNewswire– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional
- 3y agoACHLADVMAVIRBOLT+610 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical
- 3y agoACHLAchilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireLONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat
- 3y agoACHLAchilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewswire- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™
- 3y agoACHLAchilles Therapeutics to Present at Upcoming ConferencesGlobeNewswireLONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that
- 3y agoACHLAchilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewswire- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5 million supports
- 3y agoACHLAchilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell AntigensGlobeNewswireLONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
- 3y agoACHLAchilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireLONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat
- 3y agoACHLAchilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA StatusGlobeNewswire- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient's tumor - - Patent applies to any modality, including vaccine and autologous T cell
- 3y agoACHLAchilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewswireLONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced
- 3y agoACHLAchilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business HighlightsGlobeNewswire- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients - - Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of
- 3y agoACHLAchilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireLONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that
- 3y agoACHLAchilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022GlobeNewswire- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability profile potentially
- 3y agoACHLAchilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022GlobeNewswire- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging
- 3y agoACHLAchilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary MethodGlobeNewswireLONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that
- 4y agoACHLAchilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswire- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of $179.9 million supports
- 4y agoACHLAchilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswire- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - - Cell & Gene Therapy Catapult manufacturing facility approved by MHRA for cNeT production in CHIRON
- 4y agoACHLAchilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy ManufacturingGlobeNewswireLONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is leading a consortium that has been awa
- 4y agoACHLAchilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory BoardGlobeNewswireLONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business
- 4y agoACHLAchilles Therapeutics Recognized with the 2022 PING Innovation AwardGlobeNewswireLONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company was named the winner of the Phar
- 4y agoACHLAchilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswire- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma - - Expanded global manufacturing by increasing capac
- 4y agoACHLAchilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant MelanomaGlobeNewswire- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both CHIRON and THETIS and combination data from THETIS Cohort B expected in 2H 2022 - LONDON, May 0
- 4y agoACHLAchilles Therapeutics Appoints Bernhard Ehmer to Board of DirectorsGlobeNewswireLONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Boar
- 4y agoACHLAchilles Therapeutics to Present at Upcoming ConferencesGlobeNewswireLONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the follow
- 4y agoACHLThe Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy PowerhousePR NewswireStrategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy KING OF PRUSSIA, Pa., April 12, 2022 /PRNewswire/ --The Center for Breakthrough Medicines (CBM) announced today a partnership with London-based Achilles Therapeutic
- 4y agoACHLAchilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the USGlobeNewswire– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development – LONDON, April 12, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company d
- 4y agoACHLAchilles Therapeutics to Present at Upcoming ConferencesGlobeNewswireLONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will be taking part in the follo
- 4y agoACHLAchilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual MeetingGlobeNewswire- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles' AI-powered PELEUS bioinformatics platform to identify and validate clonal neoantig
- 4y agoACHLAchilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare ConferenceGlobeNewswireLONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer
- 4y agoACHLAchilles Therapeutics Selects Netrality's 401 North Broad for United States HeadquartersGlobeNewswirePHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Netrality announced today that Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, has leased 7,243 SF of lab
- 4y agoACHLAchilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business HighlightsGlobeNewswire- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and manufacturing expansion into 2H 2024 - LONDON, Mar
- 4y agoACHLAchilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.GlobeNewswireLONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Cree
- 4y agoACHLAchilles Therapeutics Provides Business Update and Outlook for 2022GlobeNewswireLONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces a business update and reflects on recent progress
- 4y agoACHLAchilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireLONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will pres
- 4y agoACHLNBIAchilles Therapeutics Added to the NASDAQ Biotechnology IndexGlobeNewswireLONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company has been added to the NASDAQ Bio
- 4y agoACHLAchilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal NeoantigensGlobeNewswire-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing- -cNeT maintain CD4+ and CD8+ T cell subsets with a highly potent polyclonal phenotype- -Dosing of patients with high-dose cNeT expected in 1H 2022- LONDON, Dec
- 5y agoACHLAchilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 ManufacturingGlobeNewswireLONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented two posters at the Society for Immunotherapy of C